Cargando…

The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis

BACKGROUND: Current first-line disease-modifying therapies (DMT) for multiple sclerosis (MS) patients are injectable or oral treatments. The Optogenerapy consortium is developing a novel bioelectronic cell-based implant for controlled release of beta-interferon (IFNβ1a) protein into the body. The cu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Visser, Laurenske A., Folcher, Marc, Delgado Simao, Claudia, Gutierrez Arechederra, Biotza, Escudero, Encarna, Uyl-de Groot, Carin A., Redekop, William Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739553/ https://www.ncbi.nlm.nih.gov/pubmed/34480325 http://dx.doi.org/10.1007/s40273-021-01081-y

Ejemplares similares

Health-related quality of life of multiple sclerosis patients: a European multi-country study
por: Visser, Laurenske A., et al.
Publicado: (2021)

Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
por: Furber, Kendra L, et al.
Publicado: (2017)

Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis
por: Yetkin, Mehmet Fatih, et al.
Publicado: (2016)

Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing–Remitting-Multiple Sclerosis Patients
por: D’Angelo, Chiara, et al.
Publicado: (2018)

Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon β-1a
por: Flechter, Shlomo, et al.
Publicado: (2011)

Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial
por: Ashtari, Fereshteh, et al.
Publicado: (2011)

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study
por: Sánchez-de la Rosa, Rainel, et al.
Publicado: (2015)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco, Eleonora, et al.
Publicado: (2015)

The innovative development in interferon beta treatments of relapsing‐remitting multiple sclerosis
por: Madsen, Claus
Publicado: (2017)

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2022)

Approved Beta Interferons in Relapsing-Remitting Multiple Sclerosis: Is There an Odd One Out?
por: Clapin, Alexis
Publicado: (2012)

The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil
por: Lemos, Livia Lovato Pires de, et al.
Publicado: (2017)

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis
por: Foley, John F., et al.
Publicado: (2013)

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)

Economic evaluations of big data analytics for clinical decision-making: a scoping review
por: Bakker, Lytske, et al.
Publicado: (2020)

How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care
por: Bakker, Lytske, et al.
Publicado: (2021)

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment
por: Zaim, Remziye, et al.
Publicado: (2023)

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2023)

Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study
por: Patti, Francesco, et al.
Publicado: (2013)

Subcutaneous Interferon β-1a Administration by Electronic Auto-injector is Associated with High Adherence in Patients with Relapsing Remitting Multiple Sclerosis in a Real-life Study
por: Järvinen, Elina, et al.
Publicado: (2017)

Interferon-β 1a and SARS Coronavirus Replication
por: Hensley, Lisa E., et al.
Publicado: (2004)

Bioelectronic cell-based device provides a strategy for the treatment of the experimental model of multiple sclerosis
por: Audouard, Emilie, et al.
Publicado: (2022)

Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study
por: Etemadifar, Masoud, et al.
Publicado: (2011)

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2021)

Deep morphea induced by interferon-β1b injection
por: Lee, Erika Yue, et al.
Publicado: (2016)

Migraine, interferon β1a and siponimod immunomodulator therapies
por: Dahaba, Ashraf A., et al.
Publicado: (2022)

Stochastic Expression of the Interferon-β Gene
por: Zhao, Mingwei, et al.
Publicado: (2012)

Interferon-β for treatment of rheumatoid arthritis?
por: van Holten, Judith, et al.
Publicado: (2002)

Epigenetic and transcriptional control of interferon-β
por: Daman, Andrew W., et al.
Publicado: (2021)

Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients
por: Seyfi, Shahram, et al.
Publicado: (2021)

Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT(®) Autoinjector: A Retrospective Cohort Study
por: Butler, Oisín, et al.
Publicado: (2021)

A Population Approach to Characterize Interferon Beta-1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis
por: Gulati, A, et al.
Publicado: (2015)

Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2018)

Thrombotic Thrombocytopenic Purpura in Interferon Beta-1a-Treated Patient Diagnosed with Relapsing-Remitting Multiple Sclerosis: A Case Report
por: Plesa, Cristina-Florentina, et al.
Publicado: (2022)

Interferon-β Signaling Contributes to Ras Transformation
por: Tsai, Yu-Chen, et al.
Publicado: (2011)

Renal thrombotic microangiopathy induced by β-interferon
por: Li Cavoli, Gioacchino, et al.
Publicado: (2011)

Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial
por: Massacesi, Luca, et al.
Publicado: (2014)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
por: Paolicelli, Damiano, et al.
Publicado: (2016)

Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia
por: Alsaqa’aby, Mai F., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7iveme2vaolqvhi6f94fijvf3b